Michael Listgarten
Algemeen Adviseur bij RAPT THERAPEUTICS, INC.
Actieve functies van Michael Listgarten
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
RAPT THERAPEUTICS, INC. | Algemeen Adviseur | 03-05-2023 | - |
Loopbaan van Michael Listgarten
Eerdere bekende functies van Michael Listgarten
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Compliance Officer | 01-02-2021 | 01-11-2021 |
PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | 01-06-2020 | 01-12-2020 |
Opleiding van Michael Listgarten
University of Pennsylvania | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Operationeel
General Counsel | 1 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
RAPT THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Michael Listgarten
- Ervaring